A patient with recalcitrant oral pemphigus vulgaris successfully treated with a biologic drug- Rituximab
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease affecting mucous membranes and the skin. Rituximab (RTX), a monoclonal antibody against CD20, has been approved by FDA for the treatment of adults with moderate to severe PV. A 42-year-old Indian woman, previously diagnosed with oral...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Online |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
International Association for Dental Research (Nigeria Division)
2019
|
| Online Erişim: | https://ajoh.oauife.edu.ng/index.php/ajoh/article/view/41 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
İlk yorumlayan siz olun!